Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 7 publications
SAPPHIRE: phase III study of sitravatinib plus nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer.
Journal: Annals of oncology : official journal of the European Society for Medical Oncology
Published: August 17, 2023
MRTX1719 Is an MTA-Cooperative PRMT5 Inhibitor That Exhibits Synthetic Lethality in Preclinical Models and Patients with MTAP-Deleted Cancer.
Journal: Cancer discovery
Published: June 14, 2023
MRTX-500 Phase 2 Trial: Sitravatinib With Nivolumab in Patients With Nonsquamous NSCLC Progressing On or After Checkpoint Inhibitor Therapy or Chemotherapy.
Journal: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
Published: December 07, 2022
A phase 1-2 trial of sitravatinib and nivolumab in clear cell renal cell carcinoma following progression on antiangiogenic therapy.
Journal: Science translational medicine
Published: April 20, 2022
Antitumor immune effects of preoperative sitravatinib and nivolumab in oral cavity cancer: SNOW window-of-opportunity study.
Journal: Journal for immunotherapy of cancer
Published: September 03, 2021
Clinical toxicity of antibody drug conjugates: a meta-analysis of payloads.
Journal: Investigational new drugs
Published: August 09, 2017
First-in-human trial of an anti-5T4 antibody-monomethylauristatin conjugate, PF-06263507, in patients with advanced solid tumors.
Journal: Investigational new drugs
Published: November 16, 2016
Showing 1-7 of 7
Last Updated: 09/26/2026